

[FIG. 1]

GASTRIC CANCER CELL




BREAST CANCER CELL

SMALL-CELL LUNG CANCER




[FIG. 2]



PANCREATIC CANCER
AsPC-1 (5000 cells)
120
100
80
60
40
20
0
*
*
*
DMSO
0.05 μ M
0.5 μ M
5 μ M
Compound X
PROSTATE CANCER
DU-145 (1000 cells)
120
100
80
60
40
20
0
*
DMSO
0.1 μ M
1 μ M
10 μ M
Compound X
KIDNEY CANCER
ACHN (4000 cells)
120
100
80
60
40
20
0
*
DMSO
0.1 μ M
1 μ M
10 μ M
Compound X
MEDULLOBLASTOMA
D341 Med (4000 cells)
120
100
80
60
40
20
0
*
*
*
DMSO
0.1 μ M
1 μ M
10 μ M
Compound X

[FIG. 3]


RHABDOMYOSARCOMA




EWING'S SARCOMA




LIPOSARCOMA




MULTIPLE MYELOMA



[FIG. 4]


Tumor Volume (mm3)
3000
2500
2000
1500
1000
500
0
0
10
20
30
40
50
60
Days After Transplantation
Non-Administration Control Group
Tumor Volume Inhibition Rate
33% Compound X (10 mg/kg)
56% gefitinib (100 mg/kg)
73% Compound X +gefitinib
*
**
**
Compound X Administration Day
Gefitinib Administration Day
* 0.0001≤p<0.05
** p<0.0001

[FIG. 5]



* : $0.01 \leq p < 0.05$, ** : $p < 0.01$